XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Total Shareholders' Equity Attributable to Bruker Corporation
Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interests in Consolidated Subsidiaries
Redeemable Noncontrolling Interest
Balance at beginning of period at Dec. 31, 2020 $ 974.3 $ 961.2 $ 1.7 $ (667.0) $ 216.3 $ 1,406.5 $ 3.7 $ 13.1  
Balance (in shares) at Dec. 31, 2020     151,987,081 22,058,529          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 1.2 1.2     1.2        
Stock options exercised (in shares)     65,312            
RSU vested (0.1) (0.1)     (0.1)        
RSU vested (in shares)     21,821            
Stock based compensation 3.4 3.4     3.4        
Shares purchased (32.8) 32.8   $ 32.8          
Shares purchased (in shares)     530,729 530,729          
Dividends declared to common stockholders (6.1) 6.1       6.1      
Consolidated net income (57.8) (56.7)       (56.7)   (1.1)  
Other comprehensive loss (16.0) (15.8)         (15.8) (0.2)  
Balance at end of period at Mar. 31, 2021 981.7 967.7 $ 1.7 $ (699.8) 220.8 1,457.1 (12.1) 14.0  
Balance (in shares) at Mar. 31, 2021     151,543,485 22,589,258          
Balance at beginning of period at Dec. 31, 2021 1,084.6 1,070.5 $ 1.7 $ (820.3) 237.8 1,659.5 (8.2) 14.1 $ 0.2
Balance (in shares) at Dec. 31, 2021     150,753,687 24,151,348          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 3.1 3.1     3.1        
Stock options exercised (in shares)     118,630            
RSU vested (in shares)     22,440            
Stock based compensation 3.8 3.8     3.8        
Shares purchased (105.6) 105.6   $ 105.6          
Shares purchased (in shares)     1,603,055 1,603,055          
Dividends declared to common stockholders (7.5) 7.5       7.5      
PreOmics Acquisition - other shareholders                 6.8
Consolidated net income (62.1) (61.6)       (61.6)   (0.5)  
Other comprehensive loss (9.2) (8.9)         (8.9) (0.3)  
Balance at end of period at Mar. 31, 2022 $ 1,031.3 $ 1,017.0 $ 1.7 $ (925.9) $ 244.7 $ 1,713.6 $ (17.1) $ 14.3 $ 6.8
Balance (in shares) at Mar. 31, 2022     149,291,702 25,754,403